Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.52 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.51 |
| ▸ | CHRNG | P07510 | 4/20 | 0.51 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.51 |
| ▸ | CHRND | Q07001 | 4/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.46 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557278 | 0.97 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1557143 | 0.94 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1556606 | 0.94 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1555907 | 0.93 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1557234 | 0.92 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1556547 | 0.90 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL2641289 | 0.89 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1556568 | 0.87 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL2641063 | 0.84 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL6255251 | 0.83 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784184-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | Targacept, Inc. (US) | 2007-05-16 | — | — | EP | claimed |
| US-20060058328-A1 | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | BHATTI BALWINDER S | 2006-03-16 | — | — | US | claimed |
| WO-2006023630-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | TARGACEPT, INC. (US) | 2006-03-02 | — | — | WO | claimed |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. | 2004-04-08 | — | — | US | claimed |
| US-20110105548-A1 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7923559-B2 | 7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane; mania, anxiety, dyslexia, schizophrenia, depression, obsessive-compulsive disorders, Tourette's syndrome | TARGACEPT, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2078718-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | Targacept, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080214591-A1 | N-Aryl Diazaspirocyclic Compounds and Methods of Preparation and Use Thereof | BHATTI BALWINDER S | 2008-09-04 | — | — | US | disclosed |
| US-7375110-B2 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7291731-B2 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1784184-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | Targacept, Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060217406-A1 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | BHATTI BALWINDER S | 2006-09-28 | — | — | US | disclosed |
| US-20060058328-A1 | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | BHATTI BALWINDER S | 2006-03-16 | — | — | US | disclosed |
| WO-2006023630-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | TARGACEPT, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20050272739-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | BHATTI BALWINDER S | 2005-12-08 | — | — | US | disclosed |
| US-6956042-B2 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214591-A1 | N-Aryl Diazaspirocyclic Compounds and Methods of Preparation and Use Thereof | TNNC1, ACHE, CHRNA6 | CHRNB2 15/4885CHRNA4 12/4885CHRNA1 16/4885 |
| US-20110105548-A1 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TNNC1, ACHE, CHRNA6 | CHRNB2 15/4885CHRNA4 12/4885CHRNA1 16/4885 |
| US-20060217406-A1 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TNNC1, ACHE, CHRNA6 | CHRNB2 14/4885CHRNA4 9/4885CHRNA1 16/4885 |
| US-20050272739-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TNNC1, ACHE, CHRNA6 | CHRNB2 14/4885CHRNA4 9/4885CHRNA1 16/4885 |
| US-20060058328-A1 | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | OPRD1, OPRK1, OPRL1 | CHRNB2 104/4885CHRNA4 66/4885CHRNA1 79/4885 |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TNNC1, ACHE, CHRNA6 | CHRNB2 14/4885CHRNA4 9/4885CHRNA1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.